DNA Vaccines Market: By Type (Human DNA Vaccines and Animal DNA Vaccines), By End user (Infectious disease, Oncology, Allergies and Veterinary Diseases), By Distribution Channel (Hospital and retail pharmacies, Government suppliers), And Region - Global Analysis of Market Size, Share & Trends For 2019-2020 And Forecasts To 2031
[170+ Pages Research Report] DNA Vaccines Market to surpass USD 781.94 billion by 2031 from USD 452.43 billion in 2021 at a CAGR of 7.4% throughout the forecast period 2021-31
DNA Vaccines are a novel approach to vaccination that uses genetically engineered small, circular bacterial DNA plasmids to elicit an immunologic response in the body. The DNA sequence also encodes the antigen against which the human body can mount an immune response. DNA vaccines are those that are made of deoxyribonucleic acid, or DNA The idea behind them is that they are delivered to cells and then the gene is expressed, resulting in the production of the required protein. Clinical trials of various DNA vaccines have yielded promising results in the treatment of various cancers, including pancreatic cancer, prostate carcinoma, metastatic melanoma, and various solid tumours. DNA vaccines employ not only the application of a DNA molecule, but also the use of adjuncts to assist the DNA molecule in entering specific target cells.
Global DNA Vaccines to surpass USD 781.94 billion by 2031 from USD 452.43 billion in 2021 at a CAGR of 7.4% in the coming years, i.e., 2021-31. The demand for DNA vaccines is rapidly increasing due to factors such as the adoption of DNA vaccines in healthcare, low cost, increasing technology, fewer side effects, increased awareness of health professionals, and others. DNA vaccines are used to kill and inhibit the growth of microorganisms. These drugs can act as a human body's defence system, neutralising the action of disease-causing agents. With increased research activities, increased awareness, and extensive R&D drugs, there is a growing demand for infectious disease treatment.
Based on type, global DNA Vaccines Market is fragmented into Human DNA Vaccines and Animal DNA Vaccines. Animal DNA vaccines are dominating the market due to the lack of human DNA vaccines on the market, as well as the rising incidence of canine melanoma and other animal diseases. Animal vaccines are third-generation vaccines that contain DNA that codes for specific pathogen proteins. This DNA is injected into the host body and produces protein, which causes the body to produce an immune response. Furthermore, the strong pipeline of human targeted vaccines is expected to aid in market growth.
Global DNA Vaccines market is classified on the basis of end user into Infectious disease, Oncology, Allergies and Veterinary Diseases. Veterinary Diseases is expected to have the highest CAGR during the forecasted period. The availability of DNA Vaccines for animal diseases such as canine melanoma vaccine (dog), West Nile Innovator (horse), life tide-SW5 (Swine and other food animals), and Apex-IHN (Salmon fish) is also expected to spur segment growth.
Based on distribution channel, global DNA Vaccines Market is segmented into Hospital and retail pharmacies, Government suppliers and Others. Hospital and retail pharmacies segment held the greatest share of the vaccines technology market owing to its availability to the general public as they are under government surveillance. Furthermore, vaccination is often conducted at smaller institutions as it is a shorter duration procedure, which is also expected to fuel segment growth.
An increase in the number of cases of cancer and infectious diseases in humans and animals, as well as an increase in demand for DNA vaccines due to benefits such as low risk of infection, easy transportation, and room temperature stability, are some of the factors driving the DNA vaccine market. With increased research activities, increased awareness, and extensive R&D drugs, there is a growing demand for infectious disease treatment.
In addition, the development of novel vaccines using DNA technology, as well as the high growth potential in untapped emerging economies, creates an opportunity for manufacturers to tap into and capitalise on the market. Furthermore, the rise in the incidence of various infectious diseases, as well as increased awareness about early disease diagnosis and prevention, drive the demand for protective vaccines, boosting market growth.
Due to high demand for the COVID-19 vaccine, manufacturers are experiencing supply issues, resulting in delays. This could limit market growth to some extent. Furthermore, due to restrictions, the supply of routine vaccines has been disrupted, negatively affecting market progression. Furthermore, a lack of understanding about the effects of DNA vaccines on humans is impeding market growth.
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Global DNA Vaccines market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. The Asia Pacific region will hold the largest share of the market due to increased public awareness of the benefits of HPV and Hepatitis B immunization. It is also expected to grow owing to factors such as rising healthcare costs and disposable income, government initiatives, and the presence of a large patient population are propelling the Asian vaccines market forward.
Get More Information - Download Free Sample
The COVID-19 disease has made a negative impact on a variety of services, including the DNA vaccine market. Nationwide lockdowns, government regulations, and an increase in infection rates in a number of countries have all had a significant financial impact on hospitals and clinics. Hospitals and clinics have seen a decrease in patient visits as a result of COVID-19, ultimately reducing client contact.
REPORT ATTRIBUTE |
DETAILS |
Market size value in 2021 |
USD 452.43 billion |
Revenue forecast in 2031 |
USD 781.94 billion |
Growth Rate |
CAGR of 7.4% from 2021 to 2031 |
Base year for estimation |
2020 |
Quantitative units |
Revenue in USD million and CAGR from 2021 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Type, End user, Distribution channel and Region |
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
Key companies profiled |
Abbott, Serum Institute of India, Pfizer, Bayer, GE Healthcare, Glaxosmithkline, Johnson and Johnson and Thermo Fisher Scientific, GlaxoSmithKline plc, and Other Prominent Players |
DNA Vaccines market size was estimated at USD 452.43 billion in 2021 and is expected to reach USD 781.94 billion in 2031.
Vaccines or immunizations are injections of a weakened form of a disease into a person, causing the body to produce antibodies or immunity against the disease.
Hospital and retail pharmacies, Veterinary Diseases and Animal vaccines segment accounted for the largest DNA Vaccines market share.
Key players: Abbott, Serum Institute of India, Pfizer, Bayer, GE Healthcare are the key players in the DNA Vaccines market.
DNA Vaccines are a novel approach to vaccination that uses genetically engineered small, circular bacterial DNA plasmids to elicit an immunologic response in the body. The DNA sequence also encodes the antigen against which the human body can mount an immune response.
Select License Type
Select License Type
FATPOS CLIENT Appriciation DURING THE PROJECT